Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03496974 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT03496974 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 38 participants.
The verdict
NCT03496974, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
A Phase 2 study of Bermekimab (MABp1) in patients with atopic dermatitis.
Interventions
- DRUG Bermekimab Monoclonal Antibody 400 mg
- DRUG Bermekimab Monoclonal Antibody 200 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2018-05-21 |
| Est. Completion | 2018-12-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03496974
The ClinicalTrials.gov registry entry for NCT03496974 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bermekimab Monoclonal Antibody 400 mg is the first listed.
NCT03496974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03496974 about?
NCT03496974 is a clinical study titled "A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis". A Phase 2 study of Bermekimab (MABp1) in patients with atopic dermatitis.
What is the current status of trial NCT03496974?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2018-05-21. Estimated completion is 2018-12-11.
What interventions are being tested in trial NCT03496974?
The interventions under investigation include: Bermekimab Monoclonal Antibody 400 mg (DRUG), Bermekimab Monoclonal Antibody 200 mg (DRUG).
Who is sponsoring clinical trial NCT03496974?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.